PANews reported on August 4th that according to Zhitong Finance, on August 4th, Hanyu Pharmaceutical and the digital asset platform Kucoin officially signed a strategic cooperation memorandum. Both parties intend to jointly explore the first RWA tokenization pilot project in mainland China with "innovative drug research and development future revenue rights" as the underlying assets. According to the agreement, Hanyu Pharmaceutical will use its technological accumulation and R&D pipeline in the GLP-1 polypeptide heavyweight drug field as the base assets, while Kucoin will leverage its advantages in blockchain technology, RWA full-process solutions, and global compliance resources to provide integrated support for the project, including on-chain mapping, asset tokenization, transaction matching, and revenue distribution.
Hanyu Pharmaceuticals and KuCoin have reached a strategic cooperation to explore the innovative drug RWA project
This article is machine translated
Show original
Sector:
Source
Disclaimer: The content above is only the author's opinion which does not represent any position of Followin, and is not intended as, and shall not be understood or construed as, investment advice from Followin.
Like
Add to Favorites
Comments
Share
